Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 5Genitourinary 2Thoracic 1Other 1NET 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Carcinoma, Hepatocellular 14Colorectal Neoplasms 13Stomach Neoplasms 12Pancreatic Neoplasms 11Liver Neoplasms 8Neuroendocrine Tumors 7Neoplasm Metastasis 6Gastrointestinal Neoplasms 4Esophageal Neoplasms 4Colonic Neoplasms 4Neoplasms 3Digestive System Neoplasms 3Gastrointestinal Stromal Tumors 2Gastro-enteropancreatic neuroendocrine tumor 2Gallbladder Neoplasms 2Cholangiocarcinoma 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Carcinoma 2Breast Neoplasms 2Adenocarcinoma Of Esophagus 2Adenocarcinoma 2Tuberous Sclerosis 1Triple Negative Breast Neoplasms 1Tongue Neoplasms 1Thrombocytosis 1Stomach Diseases 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Salivary Gland Neoplasms 1

Interventions

Trastuzumab 2Oxaliplatin 2Melphalan 2Leucovorin 2tipifarnib 1napabucasin 1irinotecan sucrosofate 1folfirinox 1Temozolomide 1Taxes 1Sunitinib 1Paclitaxel 1Irinotecan 1Interleukin-12 Subunit p35 1Interleukin-12 1Granulocyte Colony-Stimulating Factor 1Gemcitabine 1Fluorouracil 1Floxuridine 1Filgrastim 1Fentanyl 1Everolimus 1Cytokines 1Capecitabine 1Bevacizumab 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Islet Cell × Everolimus × Gastrointestinal × Clear all
NCT00363051 2013-05-10

Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy

Novartis

Phase 2 Completed
160 enrolled 17 charts
EndocrineGastrointestinalNET

Carcinoma, Neoplasms, Pancreatic Neoplasms, Carcinoma, Islet Cell, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡